Antiretroviral treatment of human immunodeficiency virus infection: Swedish recommendations.
The Swedish guidelines (SwG) for treatment of human immunodeficiency virus (HIV) infection have several important roles. A major task involves the promotion of a uniformly high standard of care in all HIV treatment clinics in Sweden and the identification of strengths, weaknesses and relevance of recent research findings. CD4+ T-cell counts < 200 cells/microl are clear indications for the initiation of treatment, whereas high viral loads serve as an indication for increased vigilance rather than a criterion for therapy. It is recommended that the first regimen consists of 2 nucleoside reverse transcriptase inhibitors in combination with 1 protease inhibitor or 1 non-nucleoside reverse transcriptase inhibitor. The definition of treatment failure is rigorous. Treatment change should be considered if the viral load has not fallen by at least 1.5 log in 4 weeks or is undetectable within 3-4 months. Resistance testing is endorsed at primary infection, in the event of treatment failure and in pregnant women. Interaction with experts in HIV resistance testing is emphasized. Therapeutic drug monitoring is advocated. Patients with treatment failure should be handled individually and the decision on therapeutic strategy should be based on treatment history, resistance testing and other clinical facts. The SwG do not give recommendations for some important issues such as prolonged drug holidays and preferences in initial treatment regimens. More scientific data are likely to be available soon and the SwG will be refined accordingly. The present guidelines are translated from Swedish; they are published on the Medical Products Agency (MPA) and Swedish Reference Group for Antiviral Therapy (RAV) websites (www.mpa.se and www.rav.nu.se), including 7 separate papers based on a thorough literature search. A complete reference list is available on request from the MPA.
Department of Venereology, South Hospital, Stockholm, Sweden.
Eric
E
Sandström
Ingrid
I
Uhnoo
Jane
J
Ahlqvist-Rastad
Göran
G
Bratt
Torsten
T
Berglund
Magnus
M
Gisslén
Stefan
S
Lindbäck
Linda
L
Morfeldt
Lars
L
Ståhle
Anders
A
Sönnerborg
D019380:Anti-HIV Agents / Q000008:administration & dosage*; D023241:Antiretroviral Therapy, Highly Active / Q000592:standards*; D005260:Female; D015658:HIV Infections / Q000175:diagnosis / Q000188:drug therapy*; D006287:Health Planning Guidelines; D006801:Humans; D008297:Male; D017410:Practice Guidelines as Topic; D011379:Prognosis; D012680:Sensitivity and Specificity; D016019:Survival Analysis; D013548:Sweden; D016896:Treatment Outcome
D019380:Anti-HIV Agents